Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML

References

• Thein MS, Ershler WB, Jemal A, et al. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119:2720–2727.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53(1):110–117.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. 2014. Cancer Facts and Figures 2013. Atlanta (GA): American Cancer Society, 201.
   Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009 Jan 1;27(1):61–69.
   PubMed Web of Science ®Google Scholar
• Wahlin A, Markevärn B, Golovleva I, et al. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001;115:25–33.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukeia Registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-labe, phase III trial of Decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Lancet JE, Wood BL, et al. Randomized phase IIb study of low dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119–128.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar 15;109(6):1114–1124.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3254.
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–1452.
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496.
   PubMed Web of Science ®Google Scholar
• Petersdorf S, Kopecky K, Stuart RK, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
   PubMed Web of Science ®Google Scholar
• ClinicaTrials.gov. NCT01690624.
   Google Scholar
• ClinicaTrials.gov. NCT01902329.
   Google Scholar
• Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455–1463.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123:554–561.
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123:356–365.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Henn A, Raum T, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549–1557.
   PubMed Web of Science ®Google Scholar
• Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27:1107–1115.
   PubMed Web of Science ®Google Scholar
• Stamova S, Cartellieri M, Feldmann A, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol. 2011;49:474–482.
   PubMed Web of Science ®Google Scholar
• ClinicaTrials.gov. NCT02520427.
   Google Scholar
• ClinicaTrials.gov. NCT01864902.
   Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–3931.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukemia: results from the LRF AML14 and NCRI AML16 pick a winner comparison. Leukemia. 2013.
   Web of Science ®Google Scholar
• Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010;115(13):2586–2591.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–4841.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012;30(32):3921–3923.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–377.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687.
   PubMed Web of Science ®Google Scholar
• Levis MPA, Perl AE, Dombret H, et al. Final results of a phase 2 open-labe, monotherapy efficacy and safety study of quizartinib (ac220) in patients with flt3-itd positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Ash Ann Meet. 2012;120(21).
   Google Scholar
• ClinicalTrials.gov. NCT01892371.
   Google Scholar
• Altman JK, Perl AE, Cortes JE, et al. Antileukemic activity and tolerability of ASP2215 80 mg and greater in FLT3 mutation-positive subjects with relapsed or refractory acute meloid leukemia: results form a phase 1/2, open-label, dose escalation/dose response study. ASH Annual Meeting; 2015 Dec 6
   Google Scholar
• Clinical Trials.gov. NCT0221939.
   Google Scholar
• Dohner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9):1426–1433.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, NCT01907815
   Google Scholar
• Swords RT, Erba PH, DeAngelo DJ, et al. Pevonedistat (MLN4924), a first-in class NED88-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodisplastic syndromes: a phase 1 study. Br J Haematol. 2015;169(4):534–543.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT02632708.
   Google Scholar
• ClinicalTrials.gov. NCT02577406.
   Google Scholar
• ClinicalTrials.gov. NCT01684150.
   Google Scholar
• Leone G, D’Alò F, Zardo G, et al. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem. 2008 Jun;15(13):1274–1287.
   PubMed Web of Science ®Google Scholar
• Laille E, Savona MR, Scott BL, et al. Pharmacokinetics of Different Formulations of Oral Azacitidine (CC-486) and the Effect of Food and Modified Gastric pH on Pharmacokinetics in Subjects With Hematologic Malignancies. J Clin Pharmacol. 2014;54(6):630
   PubMed Web of Science ®Google Scholar
• Cogle CR, Scott BL, Boyd T, et al. Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Oncologist. 2015 Dec;20(12):1404–1412.
   PubMed Web of Science ®Google Scholar
• Silverman L, Holland JF, Demakos E, et al. Azacitidine inmyelodysplastic syndromes: CALGB studies 8421 and 8921. AnnHematol. 1994;68:A12; (abstr).
   Google Scholar
• Martin MG, Walgren RA, Procknow E, et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol. 84:9550–9564.
   Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodisplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Feneaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569.
   PubMed Web of Science ®Google Scholar
• Van Der Helm LH, Veeger NJ, Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res. 2013 Aug;37(8):877–882.
   PubMed Web of Science ®Google Scholar
• Van Der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011 Dec;155(5):599–606.
   PubMed Web of Science ®Google Scholar
• Dombret HS, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840–4845.
   PubMed Web of Science ®Google Scholar
• Gupta N, Gandhi S, Miller A, et al. Comparison of epigenetic versus intensive chemotherapy for newly diagnosed acute myeloid leukemia patients _60 years old: the Roswell Park experience [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):1445.
   Web of Science ®Google Scholar
• Bally C, Adès L, Renneville A, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014 Jul;38(7):751–755.
   PubMed Web of Science ®Google Scholar
• Müller-Thomas C, Rudelius M, Rondak IC, et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2014 Oct;99(10):e179–e181.
   PubMed Web of Science ®Google Scholar
• Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010;85(2):130–138.
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff T, Modi S, et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine in patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2007;110(Abstract):819.
   Google Scholar
• Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine an cute myeloid leukemia. Leukemia. 2013;26(5):1106–1107.
   Web of Science ®Google Scholar
• DiNardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia terated with hypomethylating agents. Leuk Lymphoma. 2014;55(8):1925–1929.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–1152.
   PubMed Web of Science ®Google Scholar
• ClinicaTrials.gov. NCT02610777.
   Google Scholar
• ClinicaTrials.gov. NCT02829840.
   Google Scholar
• ClinicaTrials.gov. NCT02752035.
   Google Scholar
• ClinicaTrials.gov. NCT02706899; NCT00658814.
   Google Scholar
• ClinicaTrials.gov. NCT02677922.
   Google Scholar
• ClinicaTrials.gov. NCT00313586.
   Google Scholar
• ClinicaTrials.gov. NCT01305499.
   Google Scholar
• ClinicaTrials.gov. NCT00324220.
   Google Scholar
• ClinicaTrials.gov. NCT00392353.
   Google Scholar
• ClinicaTrials.gov. NCT00946647
   Google Scholar
• ClinicaTrials.gov. NCT01912274
   Google Scholar
• ClinicaTrials.gov. NCT02775903.
   Google Scholar
• ClinicaTrials.gov. NCT01358734.
   Google Scholar